Clinical and pathophysiological perspectives on haemostasis, inflammation, and thrombo-haemorrhagic risk in cirrhosis
DOI:
https://doi.org/10.17179/excli2026-9622Keywords:
Haemostasis, inflammation, immunohaemostasis, immunothrombosis, disease progression, cirrhosis, procedrure-related bleeding, portal vein thrombosis, venous thromboembolismAbstract
Haemostasis in cirrhosis is a dynamic process characterised by a fragile equilibrium. Haemostatic alterations become more pronounced during acute decompensation and acute-on-chronic liver failure, conditions driven by increasing systemic inflammation. When compounded by bacterial infection or acute kidney injury, additional alterations may emerge, predisposing to bleeding and thrombosis. Recent data indicate an interplay between haemostasis and inflammation in chronic liver disease, with implications for disease progression and thrombo-haemorrhagic complications. In this review, we discuss evolving knowledge across four interconnected domains. First, we summarise novel insights into the haemostatic status in cirrhosis derived from functional assays assessing platelet aggregation, total thrombus formation, thrombin and plasmin generation. Second, we examine the interplay between haemostasis and inflammation, focusing on immunohaemostasis, immunothrombosis, and coagulation-driven fibrogenesis as contributors to disease progression, with altered gut–liver axis signalling as an important upstream trigger. Third, we review evolving concepts in portal vein thrombosis and venous thromboembolism, highlighting accumulating evidence that portal vein thrombosis may represent a vascular remodelling disorder characterised by endothelial-to-mesenchymal transition, driven by portal hypertension-induced low shear stress, inflammation, infection, and gut-derived inflammatory stimuli, establishing a microenvironment permissive to secondary thrombus formation. Finally, we discuss procedure-related bleeding risk assessment, underscoring the need for a multidimensional framework integrating procedure- and patient-related factors, clinical trajectory, systemic inflammation, and functional haemostatic testing. These advances reinforce an integrated paradigm in which haemostasis, inflammation, and liver disease progression are highly interconnected. Improved understanding of this interface may enhance risk stratification and identify novel therapeutic targets in advanced chronic liver disease.
Downloads
Published
How to Cite
License
Copyright (c) 2026 Alberto Zanetto, Kymentie Ferdinande, Marco Senzolo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
- The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
- The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
- Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
- The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).
